A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults

NCT06998004

Status	RECRUITING
Phase	Phase 1
Sponsor	AstriVax Therapeutics
Enrollment	144 participants

Key Eligibility Criteria

Inclusion (4)

- Male or female between, and including, 18 and 40 years of age on the day of the Screening Visit
- Healthy individual, as established by the Investigator
- Able to read and understand the informed consent form, and written informed consent obtained from the participant
- Participants who, in the opinion of the Investigator, can and will comply with the requirements of the protocol

Exclusion (20)

- Body Mass Index \<18.0 or \>32.0 kg/m2
- Use of any investigational or non-registered product other than the study intervention within 1 month preceding study vaccination, or planned use during the study period
- Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or non-registered product
- Administration / planned administration of any vaccine not foreseen by the study protocol within 1 month preceding study vaccination and up to Day 31
- Chronic administration of immunosuppressants or other immune-modifying drugs within 6 months preceding study vaccination, or planned chronic administration at any time during the study period

... and 15 more (see full listing online)

Locations (2 total)

Centre for the Evaluation of Vaccination (CEV), Antwerp, Belgium
University Hospital Ghent - Centrum voor Vaccinologie (CEVAC), Ghent, Belgium